Lukasz R.
- Country
- Poland
- Department
- NA
Research Overview
- Phase 2a Study to Evaluate the Safety and Efficacy of Empasiprubart as Add-on Therapy to Efgartigimod in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- A Randomized, Double-Blind, Placebo-Controlled Study of AUR200 in Generalized Myasthenia Gravis
- Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study of Subcutaneous Povetacicept (ALPN‑303) in Adults with Generalized Myasthenia Gravis
Data & Insights
Has run more than one trial at 118 of 249 partner sites.
Specializations
Autoimmune Neuromuscular Disorders
This investigator specializes in various forms of myasthenia gravis, including generalized and ocular presentations. Their research encompasses both AChR-positive and AChR-antibody seronegative variants of the condition.
- Generalized Myasthenia Gravis (gMG)
- Ocular Myasthenia Gravis (oMG)
- Pediatric AChR+ gMG
Their work includes evaluation of novel therapeutic approaches including efgartigimod and gefurulimab treatments.
Inflammatory Neuropathies
The investigator focuses on treating chronic inflammatory conditions affecting the peripheral nervous system, particularly Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy.
- CIDP Management
- Multifocal Motor Neuropathy (MMN)
- Immune-mediated Neuropathies
Their research includes investigating innovative treatments such as batoclimab and DNTH103 for these conditions.
Treatment Modalities
The investigator explores diverse therapeutic approaches in neuroimmunological disorders, including both traditional and innovative treatment methods.
- Intravenous Immunoglobulin Therapy
- Subcutaneous Administration Techniques
- Novel Biological Therapeutics
Their work encompasses both established treatments like immunoglobulin therapy and emerging therapeutic agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.